A second potential COVID-19 vaccine has entered Phase 1 clinical human testing after the U.S. Food and Drug Administration (FDA) accepted an application from Inovio Pharmaceuticals.
“Inovio plans to inject its first volunteer test subject with the INO-4800 DNA vaccine candidate it has developed, following promising results from preclinical studies performed on animals that did indicate increased immune response,” Tech Crunch reported Monday.
“This is a significant step forward in the global fight against COVID-19,” Dr. J. Joseph Kim, INOVIO’s president and CEO, said in a statement.
“Without a new safe and effective vaccine, the COVID-19 pandemic is likely to continue to threaten lives and livelihoods. It also demonstrates the power of our DNA medicines platform to rapidly develop and advance a vaccine for COVID-19 into Phase 1 clinical testing. Our dedicated team of staff, partners and funders have been mobilized since the genetic sequence of the virus became available in early January and continues to work around the clock to ensure that we are rapidly advancing INO-4800 through this Phase 1 study towards planned efficacy trials.”
Tech Crunch said Inovio was able to produce thousands of doses “in part thanks to backing from the Bill and Melinda Gates Foundation, as well as funding from other nonprofits and organizations.” – READ MORE
Listen to the insightful Thomas Paine Podcast Below --